Irritable Bowel Syndrome (IBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Irritable Bowel Syndrome (IBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Irritable Bowel Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Irritable Bowel Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Irritable Bowel Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Irritable Bowel Syndrome Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Irritable Bowel Syndrome Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Irritable Bowel Syndrome Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Irritable Bowel Syndrome Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Irritable Bowel Syndrome Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Irritable Bowel Syndrome Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Irritable Bowel Syndrome Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Irritable Bowel Syndrome Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Irritable Bowel Syndrome (IBS) Therapeutics: Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.4.1 Visceral Hyperalgesia
2.4.2 Psychopathology
2.5 Symptoms
2.6 Diagnosis
2.6.1 Commonly Used Diagnosis Tests
2.7 Treatment and Management Options
2.7.1 Treatment for Lifestyle and Dietary Modifications
2.7.2 Treatment for Diarrhea and Constipation
2.7.3 Treatment for Pain or Bloating
2.8 GlobalData Pipeline Report Guidance

3 Irritable Bowel Syndrome (IBS) Therapeutics: Market Characterization
3.1 IBS Therapeutics Market Size (2005-2010) - Global
3.2 IBS Therapeutics Market Forecast (2010-2018) - Global
3.3 IBS Therapeutics Market Size (2005-2010) - The US
3.4 IBS Therapeutics Market Forecast (2010-2018) - The US
3.5 IBS Therapeutics Market Size (2005-2010) - France
3.6 IBS Therapeutics Market Forecast (2010-2018) - France
3.7 IBS Therapeutics Market Size (2005-2010) - Germany
3.8 IBS Therapeutics Market Forecast (2010-2018) - Germany
3.9 IBS Therapeutics Market Size (2005-2010) - Italy
3.10 IBS Therapeutics Market Forecast (2010-2018) - Italy
3.11 IBS Therapeutics Market Size (2005-2010) - Spain
3.12 IBS Therapeutics Market Forecast (2010-2018) - Spain
3.13 IBS Therapeutics Market Size (2005-2010) - The UK
3.14 IBS Therapeutics Market Forecast (2010-2018) - The UK
3.15 IBS Therapeutics Market Size (2005-2010) - Japan
3.16 IBS Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the IBS Therapeutics Market
3.17.1 Drivers for the IBS Therapeutics Market
3.17.2 Barriers for the IBS Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 Irritable Bowel Syndrome (IBS) Therapeutics: Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Irritable Bowel Syndrome (IBS) Therapeutics Market - Marketed Products Profile
4.2.1 Lotronex (alosetron)
4.2.2 Amitiza (lubiprostone)
4.2.3 Bentyl (dicyclomine hydrochloride)
4.2.4 Irribow (ramosetron hydrochloride)
4.3 Key Takeaway

5 Irritable Bowel Syndrome (IBS) Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 IBS Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 IBS Therapeutics - NDA Filed
5.3.2 IBS Therapeutics - Phase III Clinical Pipeline
5.3.3 IBS Therapeutics - Phase II/Phase III Clinical Pipeline
5.3.4 IBS Therapeutics - Phase II Clinical Pipeline
5.3.5 IBS Therapeutics - Phase I Clinical Pipeline
5.3.6 IBS Therapeutics - Preclinical Pipeline
5.3.7 IBS Therapeutics - Discovery Pipeline
5.4 IBS Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.5 IBS Therapeutics, Other Promising MOA
5.6 IBS Technology Trends Analytical Framework
5.7 IBS Therapeutics - Promising Drugs Under Clinical Development
5.8 Molecule Profile for Promising Drugs Under Clinical Development
5.8.1 Xifaxan (rifaximin)
5.8.2 Linaclotide
5.8.3 Asimadoline
5.8.4 Dexloxiglumide (loxiglumide-R isomer)

6 Irritable Bowel Syndrome (IBS) Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials Mapping by Sponsors
6.5 Clinical Trials Mapping by Prominent Sponsors
6.6 Participants in Therapeutic Clinical Trials - Companies

7 Irritable Bowel Syndrome (IBS) Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 IBS Therapeutics: Implications for Future Market Competition

8 Irritable Bowel Syndrome (IBS) Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Ironwood Pharmaceuticals and Forest Laboratories
8.2.2 Tioga Pharmaceuticals
8.2.3 Salix Pharmaceuticals
8.2.4 Rottapharm SpA
8.2.5 Other Companies in the IBS Therapeutics Market

9 Irritable Bowel Syndrome (IBS) Therapeutics: Licensing and Partnership Deals

10 Irritable Bowel Syndrome (IBS) Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables

Table 1: IBS Therapeutics, Prevalence, 2010
Table 2: IBS Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 3: IBS Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 4: IBS Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 5: IBS Therapeutics Market, The US, Forecasts ($m), 2010-2018
Table 6: IBS Therapeutics Market, France, Revenue ($m), 2005-2010
Table 7: IBS Therapeutics Market, France, Forecasts ($m), 2010-2018
Table 8: IBS Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 9: IBS Therapeutics Market, Germany, Forecasts ($m), 2010-2018
Table 10: IBS Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 11: IBS Therapeutics Market, Italy, Forecasts ($m), 2010-2018
Table 12: IBS Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 13: IBS Therapeutics Market, Spain, Forecasts ($m), 2010-2018
Table 14: IBS Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 15: IBS Therapeutics Market, The UK, Forecasts ($m), 2010-2018
Table 16: IBS Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 17: IBS Therapeutics Market, Japan, Forecasts ($m), 2010-2018
Table 18: IBS Therapeutics, Lotronex, Five Efficacy Studies in Women
Table 19: IBS Therapeutics, Major Marketed Products, 2011
Table 20: IBS Therapeutics, NDA Filed, 2011
Table 21: IBS Therapeutics, Phase III Clinical Pipeline, 2011
Table 22: IBS Therapeutics, Phase II/Phase III Clinical Pipeline, 2011
Table 23: IBS Therapeutics, Phase II Clinical Pipeline, 2011
Table 24: IBS Therapeutics, Phase I Pipeline, 2011
Table 25: IBS Therapeutics, Preclinical Pipeline, 2011
Table 26: IBS Therapeutics - Discovery Pipeline, 2011
Table 27: IBS Therapeutics, Other Promising Mechanisms of Action
Table 28: IBS Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 29: IBS Therapeutics - Clinical Trials by Country, 2011
Table 30: IBS Therapeutics - Clinical Trials by Phase, 2011
Table 31: IBS Therapeutics - Clinical Trials by Status (%), 2011
Table 32: IBS Therapeutics - Overall Sponsors (%), 2011
Table 33: IBS Therapeutics - Prominent Sponsors, 2011
Table 34: IBS Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 35: Ironwood Pharmaceuticals - Gastrointestinal Disorders Pipeline Portfolio, 2011
Table 36: Ironwood Pharmaceuticals - IBS Pipeline Products, 2011
Table 37: Ironwood Pharmaceuticals - Deals, 2010-11
Table 38: Tioga Pharmaceuticals - Gastrointestinal Disorders Pipeline Portfolio, 2011
Table 39: Tioga Pharmaceuticals - IBS Pipeline Products, 2011
Table 40: Tioga Pharmaceuticals - Deals, 2010-11
Table 41: Salix Pharmaceuticals - Gastrointestinal Disorders Pipeline Portfolio, 2011
Table 42: Salix Pharmaceuticals - IBS Pipeline Portfolio, 2011
Table 43: Salix Pharmaceuticals - Deals, 2010-11
Table 44: Rottapharm SpA - Gastrointestinal Disorders Pipeline Portfolio, 2011
Table 45: Rottapharm SpA - IBS Pipeline Portfolio, 2011
Table 46: Rottapharm SpA - Deals, 2009-11
Table 47: IBS Therapeutics Market, Future Players
Table 48: IBS Therapeutics, Global, Deals

1.2 List of Figures

Figure 1: IBS Therapeutics, Classification
Figure 2: IBS Therapeutics, Percentage of Men and Women with Severe IBS
Figure 3: IBS Therapeutics, IBS-Subtype Percentage Breakup
Figure 4: IBS Therapeutics, Relation Between Pathological Factors and Development
Figure 5: IBS Therapeutics, Diagnostic Algorithm
Figure 6: IBS Therapeutics, Diagnostic Criteria (Rome III)
Figure 7: IBS Therapeutics, Tests Used for Diagnosis
Figure 8: IBS Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 9: IBS Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 10: IBS Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 11: IBS Therapeutics Market, The US, Forecast ($m), 2010-2018
Figure 12: IBS Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 13: IBS Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 14: IBS Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 15: IBS Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 16: IBS Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 17: IBS Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 18: IBS Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 19: IBS Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 20: IBS Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 21: IBS Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 22: IBS Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 23: IBS Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 24: IBS Therapeutics, Constipation Predominant IBS (IBS-C), Opportunity and Unmet Need, 2011
Figure 25: IBS Therapeutics, Diarrhea Predominant IBS (IBS-D), Opportunity and Unmet Need, 2011
Figure 26: IBS Therapeutics, Alternating Form IBS (IBS-A), Opportunity and Unmet Need, 2011
Figure 27: IBS Therapeutics, Constipation Predominant IBS (IBS-C), Strategic Competitor Assessment, 2011
Figure 28: IBS Therapeutics, Diarrhea Predominant IBS (IBS-D), Strategic Competitor Assessment, 2011
Figure 29: IBS Therapeutics, Alternating Form IBS (IBS-A), Strategic Competitor Assessment, 2011
Figure 30: IBS Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 31: IBS Therapeutics, Clinical Pipeline by Mechanism of Action
Figure 32: IBS Therapeutics, Technology Trends Analytical Framework, 2011
Figure 33: IBS Therapeutics, Technology Trends Analytical Framework, Description, 2011
Figure 34: IBS Therapeutics - Clinical Trials by Country, 2011
Figure 35: IBS Therapeutics - Clinical Trials by Phase (%), 2011
Figure 36: IBS Therapeutics - Clinical Trials by Status (%), 2011
Figure 37: IBS Therapeutics - Overall Sponsors (%), 2011
Figure 38: IBS Therapeutics - Prominent Sponsors (%), 2011
Figure 39: IBS Therapeutics - Participants in Therapeutic Clinical Trials - Companies, 2011
Figure 40: IBS Therapeutics Market, Key Events Impacting the Future Market, 2011
Figure 41: Implications for Future Market Competition in the IBS Market, 2011
Figure 42: IBS Therapeutics Market, Pipeline by Company, 2011
Figure 43: GlobalData Market Forecasting Model